OTSUKA AMERICA PHARMACEUTICAL INC

OTSUKA AMERICA PHARMACEUTICAL INC specializes in the manufacturing of sterile pharmaceutical preparations, with a focused expertise in the production and supply of branded prescription medications for federal healthcare programs. Their core capabilities center on GMP-compliant drug manufacturing, including formulation development, aseptic processing, and quality control systems aligned with FDA regulations. The consistent awarding of contracts for JYNARQUE, a brand-name therapeutic for autosomal dominant polycystic kidney disease, indicates deep proficiency in managing complex, high-purity oral solid dosage forms and maintaining uninterrupted supply chains for specialty therapeutics. Their technical strengths include batch traceability, stability testing protocols, and regulatory documentation systems critical for maintaining product integrity under federal procurement standards. The Department of Veterans Affairs is their sole known federal customer, with repeated procurements demonstrating a long-standing, mission-critical relationship. These contracts reflect a reliance on OTSUKA to deliver consistent, timely access to high-cost specialty medications within the VA’s pharmacy benefit program, supporting veteran care pathways for chronic renal conditions. The recurring nature of these awards suggests a trusted supplier status with established logistics and compliance frameworks tailored to VA’s formulary and distribution requirements. Their primary industry focus is pharmaceutical preparation manufacturing under NAICS 325412, placing them squarely in the specialty drug market segment. They serve the niche of branded, FDA-approved therapeutics requiring strict adherence to manufacturing controls and post-market surveillance, positioning them as a reliable source for high-complexity, low-volume medications within the federal healthcare ecosystem. As a 2L entity headquartered in Rockville, Maryland, OTSUKA operates as a subsidiary of a larger global pharmaceutical organization, leveraging corporate infrastructure for regulatory compliance and supply chain resilience. While no specific government certifications are listed, their sustained performance under federal contracts implies robust quality management systems aligned with 21 CFR Part 211 and current Good Manufacturing Practices. Their geographic presence in a major federal biopharma hub reinforces their accessibility to key regulatory and clinical stakeholders.